CD8A and neoplasm: An analysis of immune profiles in primary tumor and paired metastasis tissue samples from patients with MSS CRCs revealed that increased expression of CD8 and PD-L1 was higher in metastatic sites following neoadjuvant FOLFOX treatment (folinic acid, 5-FU, and oxaliplatin) (209).